- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07392892
Une étude portant sur le médicament à l'étude nommé PF-08634404 en association avec une chimiothérapie dans le cancer gastro-œsophagien
UNE ÉTUDE INTERVENTIONNELLE DE PHASE 2/3 DU PF-08634404 EN COMBINAISON AVEC UNE CHIMIOTHÉRAPIE CHEZ DES PARTICIPANTS NAÏFS DE TRAITEMENT ATTEINTS D'ADÉNOCARCINOME GASTRIQUE, JONCTION GASTRO-ŒSOPHAGIENNE OU ŒSOPHAGIEN LOCALEMENT AVANCÉ OU MÉTSTATIQUE
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.
To join the study, participants must meet the following conditions:
Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.
The study has two parts:
- In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
- In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.
The treatment will be given in repeated time periods called cycles.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Pfizer CT.gov Call Center
- Numéro de téléphone: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Lieux d'étude
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Pas encore de recrutement
- London Health Sciences Centre - Verspeeten Family Cancer Centre
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510655
- Recrutement
- The Sixth Affiliated hospital, Sun Yat-sen University
-
-
Hubei
-
Wuhan, Hubei, Chine, 430079
- Recrutement
- Hubei Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine, 200031
- Recrutement
- Zhongshan Hospital,Fudan University
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- Recrutement
- Sichuan Cancer hospital
-
-
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Espagne, 08035
- Recrutement
- Hospital Universitari Vall d'Hebron
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Espagne, 28041
- Recrutement
- Hospital Universitario 12 de Octubre
-
-
Ourense [orense]
-
Ourense, Ourense [orense], Espagne, 32005
- Pas encore de recrutement
- Complexo Hospitalario Universitario de Ourense
-
-
-
-
-
Paris, France, 75015
- Recrutement
- Hôpital Européen Georges Pompidou
-
-
-
-
Central District
-
Petah Tikva, Central District, Israël, 4941492
- Recrutement
- Rabin Medical Center
-
-
HA Merkaz
-
Ramat Gan, HA Merkaz, Israël, 5265601
- Recrutement
- Sheba Medical Center
-
-
TELL ABĪB
-
Tel Aviv, TELL ABĪB, Israël, 6423906
- Recrutement
- Sourasky Medical Center
-
-
-
-
-
Milan, Italie, 20141
- Recrutement
- Istituto Europeo di Oncologia IRCCS
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 464-8681
- Recrutement
- Aichi Cancer Center
-
-
-
-
-
Bayamón, Porto Rico, 00959
- Recrutement
- Pan American Center for Oncology Trials, LLC - Bayamón Office
-
-
United States
-
Manati, United States, Porto Rico, 00674
- Recrutement
- Pan American Center for Oncology Trials, LLC - Manati Office
-
-
-
-
-
Tainan, Taïwan, 704302
- Recrutement
- National Cheng Kung University Hospital
-
Taipei, Taïwan, 10002
- Recrutement
- National Taiwan University Hospital
-
Taipei, Taïwan, 11217
- Recrutement
- Taipei Veterans General Hospital
-
-
-
-
California
-
Atascadero, California, États-Unis, 93422
- Recrutement
- UCLA Hematology/Oncology - Atascadero
-
Burbank, California, États-Unis, 91505
- Recrutement
- UCLA Hematology/Oncology - Burbank
-
Encino, California, États-Unis, 91436
- Recrutement
- UCLA Hematology/Oncology - Encino
-
Marina del Rey, California, États-Unis, 90292
- Recrutement
- UCLA Hematology/Oncology - Marina del Rey
-
Porter Ranch, California, États-Unis, 91326
- Recrutement
- UCLA Hematology/Oncology - Porter Ranch
-
San Francisco, California, États-Unis, 94158
- Pas encore de recrutement
- UCSF Helen Diller Family Comprehensive Cancer Center
-
San Francisco, California, États-Unis, 94158
- Pas encore de recrutement
- UCSF Investigational Drugs Pharmacy
-
San Luis Obispo, California, États-Unis, 93401
- Recrutement
- UCLA Hematology/Oncology - San Luis Obispo
-
Santa Barbara, California, États-Unis, 93101
- Recrutement
- UCLA Hematology/Oncology - Santa Barbara
-
Santa Monica, California, États-Unis, 90404
- Recrutement
- UCLA Hematology/Oncology - Santa Monica
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80012
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Boulder, Colorado, États-Unis, 80303
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Centennial, Colorado, États-Unis, 80112
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, États-Unis, 80907
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Colorado Springs, Colorado, États-Unis, 80923
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, États-Unis, 80218
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Denver, Colorado, États-Unis, 80220
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Englewood, Colorado, États-Unis, 80113
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Lakewood, Colorado, États-Unis, 80228
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Littleton, Colorado, États-Unis, 80120
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Lone Tree, Colorado, États-Unis, 80124
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Longmont, Colorado, États-Unis, 80504
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Pueblo, Colorado, États-Unis, 81003
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
Thornton, Colorado, États-Unis, 80260
- Recrutement
- Rocky Mountain Cancer Centers, LLP
-
-
Florida
-
Daytona Beach, Florida, États-Unis, 32117
- Pas encore de recrutement
- Florida Cancer Specialists
-
Fleming Island, Florida, États-Unis, 32003
- Pas encore de recrutement
- Florida Cancer Specialists
-
Palm Beach Gardens, Florida, États-Unis, 33410
- Pas encore de recrutement
- Florida Cancer Specialists
-
Sebring, Florida, États-Unis, 33870
- Pas encore de recrutement
- Florida Cancer Specialists
-
Wellington, Florida, États-Unis, 33414
- Pas encore de recrutement
- Florida Cancer Specialists
-
West Palm Beach, Florida, États-Unis, 33401
- Pas encore de recrutement
- Florida Cancer Specialists
-
-
Illinois
-
Arlington Heights, Illinois, États-Unis, 60005
- Recrutement
- Illinois Cancer Specialists
-
Bloomington, Illinois, États-Unis, 61704
- Recrutement
- Illinois CancerCare - Bloomington
-
Chicago, Illinois, États-Unis, 60631
- Recrutement
- Illinois Cancer Specialists
-
Galesburg, Illinois, États-Unis, 61401
- Recrutement
- Illinois CancerCare - Galesburg
-
Niles, Illinois, États-Unis, 60714
- Recrutement
- Illinois Cancer Specialists
-
Ottawa, Illinois, États-Unis, 61350
- Recrutement
- Illinois CancerCare-Ottawa-Fox River Cancer Center
-
Pekin, Illinois, États-Unis, 61554
- Recrutement
- Illinois CancerCare-Pekin
-
Peoria, Illinois, États-Unis, 61615
- Recrutement
- Illinois CancerCare, P.C.
-
Peru, Illinois, États-Unis, 61354
- Recrutement
- Illinois CancerCare-Peru - Valley Regional Cancer Center
-
Washington, Illinois, États-Unis, 61571
- Recrutement
- Illinois CancerCare-Washington
-
-
Maryland
-
Annapolis, Maryland, États-Unis, 21401
- Recrutement
- Maryland Oncology Hematology, P.A.
-
Bethesda, Maryland, États-Unis, 20817
- Recrutement
- Maryland Oncology Hematology, P.A.
-
Brandywine, Maryland, États-Unis, 20613
- Recrutement
- Maryland Oncology Hematology, P.A.
-
Columbia, Maryland, États-Unis, 21044
- Recrutement
- Maryland Oncology Hematology, P.A.
-
Germantown, Maryland, États-Unis, 20876
- Recrutement
- Maryland Oncology Hematology, P.A.
-
Largo, Maryland, États-Unis, 20774
- Recrutement
- Maryland Oncology Hematology, P.A.
-
Rockville, Maryland, États-Unis, 20850
- Recrutement
- Maryland Oncology Hematology, P.A.
-
Silver Spring, Maryland, États-Unis, 20904
- Recrutement
- Maryland Oncology Hematology, P.A.
-
-
Nevada
-
Reno, Nevada, États-Unis, 89502
- Recrutement
- Renown Regional Medical Center
-
Reno, Nevada, États-Unis, 89502
- Recrutement
- Renown Health Medical Oncology
-
Reno, Nevada, États-Unis, 89502
- Recrutement
- Renown Office of Clinical Research
-
-
New Jersey
-
Morristown, New Jersey, États-Unis, 07960
- Pas encore de recrutement
- Atlantic Health System
-
Summit, New Jersey, États-Unis, 07901
- Pas encore de recrutement
- Atlantic Health System / Overlook Medical Center
-
-
New York
-
Long Island City, New York, États-Unis, 11101
- Recrutement
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
-
Long Island City, New York, États-Unis, 11101
- Recrutement
- Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
-
New York, New York, États-Unis, 10065
- Recrutement
- Memorial Sloan Kettering Cancer Center - Main Campus
-
New York, New York, États-Unis, 10021
- Recrutement
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
-
New York, New York, États-Unis, 10022
- Recrutement
- Rockefeller Outpatient Pavilion (53rd Street)
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45245
- Recrutement
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, États-Unis, 45242
- Recrutement
- Oncology Hematology Care Clinical Trials, LLC
-
Cincinnati, Ohio, États-Unis, 45211
- Recrutement
- Oncology Hematology Care Clinical Trials, LLC
-
Fairfield, Ohio, États-Unis, 45014
- Recrutement
- Oncology Hematology Care Clinical Trials, LLC
-
-
Pennsylvania
-
Bensalem, Pennsylvania, États-Unis, 19020
- Recrutement
- Alliance Cancer Specialists, PC
-
Doylestown, Pennsylvania, États-Unis, 18901
- Recrutement
- Alliance Cancer Specialists, PC
-
Horsham, Pennsylvania, États-Unis, 19044
- Recrutement
- Alliance Cancer Specialists, PC
-
Langhorne, Pennsylvania, États-Unis, 19047
- Recrutement
- Alliance Cancer Specialists, PC
-
Media, Pennsylvania, États-Unis, 19063
- Recrutement
- Alliance Cancer Specialists, PC
-
Sellersville, Pennsylvania, États-Unis, 18960
- Recrutement
- Alliance Cancer Specialists, PC
-
Wynnewood, Pennsylvania, États-Unis, 19096
- Recrutement
- Alliance Cancer Specialists, PC
-
-
Texas
-
Irving, Texas, États-Unis, 75063
- Recrutement
- US Oncology Investigational Products Center (IPC)
-
-
Virginia
-
Arlington, Virginia, États-Unis, 22201
- Recrutement
- Virginia Cancer Specialists, PC
-
Chesapeake, Virginia, États-Unis, 23320
- Recrutement
- Virginia Oncology Associates
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Virginia Cancer Specialists, PC
-
Hampton, Virginia, États-Unis, 23666
- Recrutement
- Virginia Oncology Associates
-
Manassas, Virginia, États-Unis, 20110
- Recrutement
- Virginia Cancer Specialists, PC
-
Newport News, Virginia, États-Unis, 23606
- Recrutement
- Virginia Oncology Associates
-
Norfolk, Virginia, États-Unis, 23502
- Recrutement
- Virginia Oncology Associates
-
Reston, Virginia, États-Unis, 20190
- Recrutement
- Virginia Cancer Specialists, PC
-
Virginia Beach, Virginia, États-Unis, 23456
- Recrutement
- Virginia Oncology Associates
-
Woodbridge, Virginia, États-Unis, 22191
- Recrutement
- Virginia Cancer Specialists, PC
-
-
Washington
-
Seattle, Washington, États-Unis, 98195
- Recrutement
- University of Washington Medical Center
-
Seattle, Washington, États-Unis, 98109
- Recrutement
- Fred Hutchinson Cancer Center
-
Seattle, Washington, États-Unis, 98104
- Recrutement
- Harborview Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
- Evidence of locally advanced or metastatic disease.
- Eastern Cooperative Oncology Group performance status (ECOG) 0-1
- No prior systemic therapy for advanced or metastatic disease.
- Adequate hepatic, liver, and renal function
- HER-2 negative status based on local testing
- PD-L1 positive status based on local testing
Exclusion Criteria:
- Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
- Clinically significant risk of hemorrhage or fistula
- Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
- History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
- Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
- Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
- Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
- Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase 2 Portion
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Autres noms:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Expérimental: Phase 3: Arm A
PF-08634404 + Chemotherapy |
Participants will receive PF-08634404 intravenously.
Autres noms:
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. |
|
Comparateur actif: Phase 3: Arm B
Nivolumab + Chemotherapy |
Participants will receive PF-08634404 intravenously in combination with Chemotherapy. Participants will receive Nivolumab intravenously. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Délai: Approximately 4 years
|
Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 2: Number of participants with treatment-emergent adverse events
Délai: Through 90 days after the last study intervention; Approximately 4 years
|
Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Délai: Approximately 4 years
|
PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: Overall Survival (OS)
Délai: Approximately 4 years
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Approximately 4 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 2 : Incidence des anticorps anti-médicament (ADA) contre le PF-08634404
Délai: Environ 21 mois
|
Environ 21 mois
|
|
|
Phase 3 : Incidence des ADA contre le PF-08634404
Délai: Environ 21 mois
|
Environ 21 mois
|
|
|
Phase 3 : Évolution par rapport à la valeur initiale du score total de l'évaluation fonctionnelle des thérapies anticancéreuses - Gastrique (FACT-Ga)
Délai: Environ 4 ans
|
Environ 4 ans
|
|
|
Phase 3 : Temps jusqu'à la détérioration définitive du score total FACT-Ga
Délai: Approximativement 4 ans
|
Approximativement 4 ans
|
|
|
Phase 3 : Temps jusqu'à la détérioration définitive du score de l'échelle du cancer gastrique (GaCS)
Délai: Environ 4 ans
|
Environ 4 ans
|
|
|
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Délai: Approximately 4 years
|
DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Délai: Approximately 4 years
|
PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 2: Overall Survival (OS)
Délai: Approximately 4 years
|
OS is defined as the time from the date of first dose to the date of death due to any cause. |
Approximately 4 years
|
|
Phase 2: Number of participants with laboratory abnormalities
Délai: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 2: Serum concentrations of PF-08634404
Délai: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
|
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Délai: Approximately 4 years
|
ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR. |
Approximately 4 years
|
|
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Délai: Approximately 4 years
|
ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator. |
Approximately 4 years
|
|
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Délai: Approximately 4 years
|
PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Délai: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Délai: Approximately 4 years
|
DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first. |
Approximately 4 years
|
|
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Délai: Approximately 4 years
|
PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first |
Approximately 4 years
|
|
Phase 3: Number of participants with treatment-emergent adverse events
Délai: Through 90 days after the last study intervention; Approximately 4 years
|
AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s) |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Number of participants with laboratory abnormalities
Délai: Through 90 days after the last study intervention; Approximately 4 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed. |
Through 90 days after the last study intervention; Approximately 4 years
|
|
Phase 3: Serum concentrations of PF-08634404
Délai: Approximately 21 months
|
Predose and postdose concentrations of PF-08634404 |
Approximately 21 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Pfizer CT.gov Call Center, Pfizer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Maladies de l'estomac
- Tumeurs de l'estomac
- Adénocarcinome de l'oesophage
- Acides aminés, peptides et protéines
- Protéines
- Thérapeutique
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Nivolumab
- Pharmacothérapie
Autres numéros d'identification d'étude
- C6461016
- 2025-524717-86-00 (Identificateur de registre: CTIS (EU))
- 2025 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .